{"id":"invirase","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Gastritis","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Flatulence","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Hepatitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyperglycemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypertriglyceridemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Weakness","drugRate":"","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Alcoholism","Breastfeeding (mother)","Chronic hepatitis C","Chronic type B viral hepatitis","Cirrhosis of liver","Complete atrioventricular block","Congenital long QT syndrome","Diabetes mellitus","Disease of liver","Hepatic failure","Hereditary factor IX deficiency disease","Hereditary factor VIII deficiency disease","Hypercholesterolemia","Hyperglycemia","Hypertriglyceridemia","Hypokalemia","Hypomagnesemia","Liver function tests abnormal","Prolonged QT interval","Second degree atrioventricular block","Torsades de pointes","Viral hepatitis C"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Hepatocellular toxicity","drugRate":"65%","severity":"serious"},{"effect":"Increased hepatic transaminases (>20-fold ULN)","drugRate":"65%","severity":"serious"},{"effect":"Pancreatitis","drugRate":"","severity":"serious"},{"effect":"Esophagitis","drugRate":"","severity":"serious"},{"effect":"Portal hypertension","drugRate":"","severity":"serious"},{"effect":"Hepatosplenomegaly","drugRate":"","severity":"serious"},{"effect":"Intestinal obstruction","drugRate":"","severity":"serious"},{"effect":"Syncope","drugRate":"","severity":"serious"},{"effect":"Thrombophlebitis","drugRate":"","severity":"serious"},{"effect":"Wasting syndrome","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Invirase","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:10:05.028342+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:10:17.548857+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Invirase","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:10:18.349091+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Human immunodeficiency virus type 1 protease inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:10:18.943110+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL282042/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:10:18.821976+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"b8b53129-06ab-4143-b9b7-7675e49a52ef","title":"INVIRASE (SAQUINAVIR MESYLATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY]"},"ecosystem":[],"mechanism":{"target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, Multidrug resistance protein 1"},"_scrapedAt":"2026-03-28T01:16:59.279Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:10:20.698657+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Human immunodeficiency virus infection","diseaseId":"human-immunodeficiency-virus-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00056641","phase":"PHASE2","title":"Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-02-18","conditions":"HIV Infections","enrollment":328},{"nctId":"NCT00003008","phase":"PHASE2","title":"Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-12-15","conditions":"Sarcoma","enrollment":33},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00000891","phase":"PHASE2","title":"Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00000848","phase":"PHASE2","title":"The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":144},{"nctId":"NCT00000892","phase":"NA","title":"A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00000906","phase":"PHASE1","title":"Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00051831","phase":"NA","title":"Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-10","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT00001108","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00102206","phase":"PHASE2","title":"A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00005762","phase":"NA","title":"Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-03","conditions":"HIV Infections","enrollment":90},{"nctId":"NCT00084058","phase":"PHASE1, PHASE2","title":"Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT00001133","phase":"PHASE1","title":"Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00000898","phase":"NA","title":"The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT00000920","phase":"PHASE1","title":"Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Pregnancy","enrollment":24},{"nctId":"NCT00000914","phase":"NA","title":"A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":800},{"nctId":"NCT00000913","phase":"PHASE2","title":"A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00000941","phase":"PHASE1","title":"A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT00000912","phase":"PHASE2","title":"A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":475},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01232361","phase":"","title":"IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-10-08","conditions":"ADHD, HIV","enrollment":127},{"nctId":"NCT00145561","phase":"PHASE1, PHASE2","title":"The Pharmacokinetic Study of Saquinavir New Tablet Formulation in HIV-infected Pregnant Women.","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2005-08","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT00307502","phase":"PHASE1","title":"Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV Infections","enrollment":675},{"nctId":"NCT00379405","phase":"PHASE4","title":"Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2006-06","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00435929","phase":"PHASE1","title":"A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-09","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT00050180","phase":"PHASE4","title":"Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2002-11-22","conditions":"Healthy, HIV Infections","enrollment":81},{"nctId":"NCT00100984","phase":"PHASE4","title":"A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2004-07-21","conditions":"HIV Infection","enrollment":8},{"nctId":"NCT01814722","phase":"","title":"Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-09","conditions":"Human Immunodeficiency Virus","enrollment":63},{"nctId":"NCT01297127","phase":"","title":"Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-08","conditions":"HIV Infections","enrollment":151},{"nctId":"NCT01638650","phase":"PHASE1","title":"A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-01","conditions":"HIV Infections","enrollment":23},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT00623597","phase":"PHASE2","title":"A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT00477048","phase":"PHASE2","title":"Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2004-05","conditions":"IDV Associated Nephrotoxicity","enrollment":30},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT00665847","phase":"PHASE2","title":"TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-11","conditions":"HIV-1","enrollment":103},{"nctId":"NCT00476983","phase":"PHASE2, PHASE3","title":"Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg","status":"WITHDRAWN","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"","conditions":"Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID","enrollment":""},{"nctId":"NCT00476359","phase":"PHASE4","title":"A PK and Salvage Study for Children With HIV-infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-10","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00622141","phase":"PHASE1, PHASE2","title":"Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir®","status":"WITHDRAWN","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00001094","phase":"PHASE2","title":"A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT02239835","phase":"PHASE2","title":"Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"1999-12","conditions":"HIV Infections","enrollment":79},{"nctId":"NCT02023450","phase":"EARLY_PHASE1","title":"Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2013-12","conditions":"Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT02184286","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"1999-05","conditions":"HIV Infections","enrollment":5},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00000918","phase":"PHASE2","title":"A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":"HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease","enrollment":80},{"nctId":"NCT00622206","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Low Dose Ritonavir","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-01","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT00476502","phase":"","title":"Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2006-02","conditions":"HIV Infections","enrollment":250},{"nctId":"NCT00400738","phase":"PHASE2","title":"The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2004-03","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT00122603","phase":"PHASE2","title":"Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2005-12","conditions":"HIV Infections","enrollment":61},{"nctId":"NCT00105079","phase":"PHASE3","title":"GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-04","conditions":"HIV Infections","enrollment":337},{"nctId":"NCT00438152","phase":"PHASE4","title":"Lopinavir Capsules to Kaletra or Invirase Tablets","status":"COMPLETED","sponsor":"Royal Free Hampstead NHS Trust","startDate":"2006-09","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT00004584","phase":"PHASE2","title":"Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-12","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00046033","phase":"PHASE2","title":"Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":118},{"nctId":"NCT00001040","phase":"PHASE2","title":"Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00035932","phase":"PHASE3","title":"Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-11","conditions":"HIV Infections","enrollment":571},{"nctId":"NCT00717067","phase":"PHASE4","title":"Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2008-07","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":30},{"nctId":"NCT00389402","phase":"PHASE4","title":"BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes","status":"COMPLETED","sponsor":"International Antiviral Therapy Evaluation Center","startDate":"2006-07","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00192608","phase":"NA","title":"A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-11","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00038532","phase":"PHASE2","title":"Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART","status":"COMPLETED","sponsor":"Abbott","startDate":"2001-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00043953","phase":"PHASE2","title":"Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-08","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00038519","phase":"PHASE2, PHASE3","title":"Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor","status":"COMPLETED","sponsor":"Abbott","startDate":"2001-04","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT00285883","phase":"PHASE3","title":"Directly Observed Therapy in High Risk Populations in Newark, NJ","status":"COMPLETED","sponsor":"Saint Michael's Medical Center","startDate":"2004-04","conditions":"Directly Observed Therapy, HIV Infections","enrollment":30},{"nctId":"NCT00002425","phase":"PHASE4","title":"The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":400},{"nctId":"NCT00002378","phase":"PHASE3","title":"A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":825},{"nctId":"NCT00002334","phase":"PHASE3","title":"A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":3000},{"nctId":"NCT00002333","phase":"PHASE2","title":"A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":900},{"nctId":"NCT00002383","phase":"PHASE1","title":"A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00002229","phase":"PHASE4","title":"Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00002178","phase":"PHASE3","title":"A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":375},{"nctId":"NCT00002190","phase":"PHASE2","title":"A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00002382","phase":"PHASE3","title":"A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":4000},{"nctId":"NCT00002367","phase":"PHASE3","title":"A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00002184","phase":"PHASE2","title":"A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00002372","phase":"PHASE1","title":"A Study of 141W94 in Combination With Other Anti-HIV Drugs","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT00002448","phase":"PHASE3","title":"A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"1999-10","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00002111","phase":"PHASE1","title":"A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.","status":"COMPLETED","sponsor":"Stanford University","startDate":"","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT00002380","phase":"PHASE1","title":"The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":28},{"nctId":"NCT00002440","phase":"PHASE2","title":"A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00002162","phase":"PHASE2","title":"A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":140},{"nctId":"NCT00002347","phase":"PHASE2","title":"The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection","status":"COMPLETED","sponsor":"Parexel","startDate":"","conditions":"HIV Infections","enrollment":225},{"nctId":"NCT00002374","phase":"PHASE3","title":"A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00002397","phase":"PHASE3","title":"A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections, AIDS-Associated Nephropathy","enrollment":24},{"nctId":"NCT00002447","phase":"PHASE3","title":"A Study to Compare Two Anti-HIV Drug Combinations","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"1999-10","conditions":"HIV Infections","enrollment":146}],"_emaApprovals":[],"_faersSignals":[{"count":89,"reaction":"PAIN"},{"count":88,"reaction":"ANXIETY"},{"count":87,"reaction":"EMOTIONAL DISTRESS"},{"count":76,"reaction":"ANHEDONIA"},{"count":66,"reaction":"DRUG EXPOSURE DURING PREGNANCY"},{"count":58,"reaction":"RENAL FAILURE"},{"count":55,"reaction":"DEPRESSION"},{"count":54,"reaction":"ANAEMIA"},{"count":50,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":49,"reaction":"PYREXIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL282042"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":73,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Invirase","genericName":"Invirase","companyName":"Saint Michael's Medical Center","companyId":"saint-michael-s-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:10:20.698657+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}